Pancreatitis risk with DPP4 inhibitors

Acute pancreatitis is now listed as a possible adverse effect of all dipeptidyl peptidase 4 (DPP4) inhibitors ('gliptins').

The mechanism by which DPP4 inhibitors might increase the risk of pancreatitis is unknown | SCIENCE PHOTO LIBRARY
The mechanism by which DPP4 inhibitors might increase the risk of pancreatitis is unknown | SCIENCE PHOTO LIBRARY

Drugs of this class, which are used in the treatment of type II diabetes, include Galvus (vildagliptin), Januvia (sitagliptin), Onglyza (saxagliptin), Trajenta (linagliptin), and the combination tablets Eucreas (metformin + vildagliptin), Janumet (metformin + sitagliptin) and Jentadueto (metformin + linagliptin).

When to suspect pancreatitis

Characteristic symptoms of acute pancreatitis include persistent, severe abdominal pain, sometimes radiating to the back. The MHRA advises that all patients taking a DPP4 inhibitor should be informed of these symptoms and encouraged to report any occurrence. Treatment should be discontinued if pancreatitis is suspected. 

Follow MIMS on Twitter

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Calcium and Vitamin D Supplements for Osteoporosis

Calcium and Vitamin D Supplements for Osteoporosis

Formulations, doses and costs of osteoporosis supplements.

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Topical Steroids, Comparison of Potencies and Formulations

Topical Steroids, Comparison of Potencies and Formulations

Strengths and formulations of topical steroids.

Topical Steroids, Potential Skin Sensitisers as Ingredients

Topical Steroids, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in topical steroids.